Department of Biophysics, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Moscow, Russian Federation.
PLoS One. 2020 May 29;15(5):e0227932. doi: 10.1371/journal.pone.0227932. eCollection 2020.
For many pathological states, microparticles are supposed to be one of the causes of hypercoagulation. Although there are some indirect data about microparticles participation in coagulation activation and propagation, the integral hemostasis test Thrombodynamics allows to measure micropaticles participation in these two coagulation phases directly. Demonstrates microparticles participation in coagulation activation by influence on the appearance of coagulation centres in the plasma volume and the rate of clot growth from the surface with immobilized tissue factor.Methods: Microparticles were obtained from platelets and erythrocytes by stimulation with thrombin receptor-activating peptide (SFLLRN) and calcium ionophore (A23187), respectively, from monocytes, endothelial HUVEC culture and monocytic THP cell culture by stimulation with lipopolysaccharides. Microparticles were counted by flow cytometry and titrated in microparticle-depleted normal plasma in the Thrombodynamics test.
Monocyte microparticles induced the appearance of clotting centres through the TF pathway at concentrations approximately 100-fold lower than platelet and erythrocyte microparticles, which activated plasma by the contact pathway. For endothelial microparticles, both activation pathways were essential, and their activity was intermediate. Monocyte microparticles induced plasma clotting by the appearance of hundreds of clots with an extremely slow growth rate, while erythrocyte microparticles induced the appearance of a few clots with a growth rate similar to that from surface covered with high-density tissue factor. Patterns of clotting induced by platelet and endothelial microparticles were intermediate. Platelet, erythrocyte and endothelial microparticles impacts on the rate of clot growth from the surface with tissue factor did not differ significantly within the 0-200·103/ul range of microparticles concentrations. However, at concentrations greater than 500·103/ul, erythrocyte microparticles increased the stationary clot growth rate to significantly higher levels than do platelet microparticles or artificial phospholipid vesicles consisting of phosphatidylcholine and phosphatidylserine.
Microparticles of different origins demonstrated qualitatively different characteristics related to coagulation activation and propagation.
对于许多病理状态,微粒被认为是导致高凝状态的原因之一。尽管有一些关于微粒参与凝血激活和传播的间接数据,但整体止血测试 Thrombodynamics 可以直接测量微粒在这两个凝血阶段的参与情况。方法:通过刺激血小板和红细胞中的凝血酶受体激活肽(SFLLRN)和钙离子载体(A23187)分别从单核细胞、内皮 HUVEC 培养物和单核细胞 THP 细胞培养物中获得微粒,通过刺激单核细胞中的脂多糖获得微粒。通过流式细胞术计数微粒,并在 Thrombodynamics 测试中在微粒耗竭的正常血浆中滴定。结果:单核细胞微粒通过 TF 途径在大约比血小板和红细胞微粒低 100 倍的浓度下诱导凝血中心的出现,这些微粒通过接触途径激活血浆。对于内皮微粒,两种激活途径都是必需的,其活性处于中间水平。单核细胞微粒通过出现数百个生长速度极慢的血凝块诱导血浆凝血,而红细胞微粒通过出现与覆盖高密度组织因子表面相似的生长速度的少数血凝块诱导凝血。血小板和内皮微粒诱导的凝血模式处于中间水平。在 0-200·103/ul 范围内的微粒浓度范围内,血小板、红细胞和内皮微粒对表面组织因子生长速度的影响没有显著差异。然而,在浓度大于 500·103/ul 时,红细胞微粒使静止血凝块生长速度显著高于血小板微粒或由磷脂酰胆碱和磷脂酰丝氨酸组成的人工磷脂囊泡。结论:不同来源的微粒表现出与凝血激活和传播相关的定性不同的特征。